Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats

International Journal of Pharmaceutics

Volumn 280, Issue 1-2, 2004, Pages 221-227

  Choi, Jun Shik ^a   Jo, Byung Wok ^a  

^a Chosun University   (South Korea)

Author keywords

Bioavailability; Paclitaxel; PEGylated prodrug; Pharmacokinetics

Indexed keywords

PACLITAXEL; PRODRUG;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; MALE; PACLITAXEL; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 3242736466     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2004.05.014     Document Type: Article

References (30)

1. Brown T., Havlin K., Weiss G., Cagnola J., Koeller J., Kuhn J., Rizzo J., Craig J., Phillips J., Von Hoff D. A Phase 1 trial of taxol given by a 6-hour intravenous infusion. J. Clin. Oncol. 9:1991;1261-1267
2. Choi J.S., Jo B.W., Kim Y.C. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur. J. Pharmaceut. Biopharmaceut. 57:2004;313-318
3. Cresteil T., Monsarrat B., Alvinerie P., Trèluyer J.M., Vieira I., Wright M. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotranformation. Cancer Res. 54:1994;386-392
4. Gan L.-S.L., Moseley M.A., Khosla B., Augustijns P.F., Bradshaw T.P., Hendren R.W., Thakker D.R. CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos. 24:1996;344-349
5. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427
6. Hiroshi F., Masaaki O., Ayuko T., Hideshi M., Hiroyuki K. Pharmacokinetics of Paclitaxel in experimental animals. Part 2. Tissue distribution. Jpn. J. Cancer Chemother. 21:1994;659-664
7. Holmes F.A., Walters R.S., Theriault R.L., Forman A.D., Newton L.K., Raber M.N., Buzdar A.U., Frye D.K., Hortobagyi G.N. Phase 2 trial of taxol an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst. 83:1991;1797-1805
8. Ito K., Kusuhara H., Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm. Res. 16:1999;225-231
9. Jo, B.W., Korean Patent 2000-0019873 (2000).
10. Jo, B.W., Kolon Inc., US Patent (2004).
11. Jo B.W., Hess M., Zahres M. Self-diffusion of poly(ethylene oxide)-modified paclitaxel in dilute aqueous solutions. Mater. Res. Innovat. 7:2003;178-182
12. Kumar N. Taxol-induced polymerization of purified tubulin. Mechanism of action. J. Biol. Chem. 256:1981;10435-10441
13. Kumar G.N., Walle U.K., Walle T. Cytochrome P450 3A-mediated human liver microsomal taxol 6α-hydroxylation. J. Pharmacol. Exp. Ther. 268:1994;1160-1165
14. Lee S.H., Yoo S.D., Lee K.H. Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography. J. Chromatogr. B. Biomed. Sci. Appl. 724:1999;357-363
15. Manfedi J.J., Horwitz S.B. An antimitotic agent with a new mechanism of action. Pharmacol. Ther. 25:1984;83-125
16. McGuire W.P., Rowinsky E.K., Rosenheim N.B., Grumbine F.C., Ettinger D.S., Armstrong D.K., Donehower R.C. Taxol: a unique antineoplasic agent with significant activity in advanced ovarian epithelial neoplasm. Ann. Int. Med. 111:1989;273-279
17. Rahman A., Korzekwa K.R., Grogan J., Gonzalezs F.J., Harris J.W. Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54:1994;5543-5546
18. Rocci M.L., Jusko W.J. LAGRAN program for area and moments in pharmacokinetic analysis. Comput. Prog. Biomed. 16:1983;203-216
19. ®). Sem. Oncol. 20:1993;1-15
20. Rowinsky E.K., Cazenave L.A., Donehower R.C. Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst. 82:1990;1247-1259
21. Sarosy G., Kohn E., Stone D.A., Rothenberg M., Jacob J., Adamo D.O., Ognibene F.P., Cunnion R.E., Reed E. Phase 1 study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J. Clin. Oncol. 10:1992;1165-1170
22. Sohn J.S., Choi S.K., Hess M., Jo B.W. Polymer-modification of an anti-cancer drug: effects on hydrodynamic propreties. Macromol. Symp. 201:2003;163-170
23. Sonnichsen D.S., Liu Q., Schuetz E.G., Schuetz J.D., Pappo A., Relling M.V. Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmacol. Exp. Ther. 275:1995;566-575
24. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., Borst P., Nooijen W.J., Bejinen J.H., van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U.S.A. 4:1997;2031-2035
25. Wacher V.H., Silverman J.A., Zhang Y., Benet L.Z. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87:1998;1322-1330
26. Walle T., Walle U.K., Kumar G.N., Bhalla K.N. Taxol metabolism and disposition in cancer patients. Durg Metab. Disp. 23:1995;506-512
27. Wani M.C., Taylor H.L., Wall M.E., Coggon P., McPhail A.T. Plant antitumor agnets. Part VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93:1971;2325-2327
28. Watkins P.B. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27:1996;161-170
29. Wiernik P.H., Schwartz E.L., Strauman J.J., Dutcher J.P., Lipton R.B., Paietta E. Phase 1 clinical and pharmacokinetic study of taxol. Cancer Res. 47:1987a;2486-2493
30. Wiernik P.H., Schwartz E.L., Einzig A., Strauman J.J., Lipton R.B., Dutcher J.P. Phase trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J. Clin. Oncol. 5:1987b;1232-1239